Tricida, Inc. is an innovative pre-clinical stage biopharmaceutical company, founded in 2013, and focused on the discovery and development of first-in-class therapeutics for metabolic, renal and cardiovascular disease. Tricida’s lead program is TRC101, a novel treatment for complications of chronic kidney disease (CKD). Tricida is led by an experienced and accomplished management team that has worked together for 10 plus years and has raised >$250 M in venture capital from world-class investors over three companies. This team brings their proven leadership and expertise to address the specific disease profile of chronic kidney disease and related complications. The National Health and Nutrition Examination Surveys (NHANES, 1988-1994 and 1999-2004) estimate that over 26 million adults in the United States have chronic kidney disease, with substantial morbidity and mortality associated with the progressive loss of kidney function. The scientists and clinicians at Tricida aim to provide physicians with new drug treatment options to help control the disease and reduce the number of CKD patients requiring dialysis. Tricida’s shared culture of teamwork, comradery and empowerment is evident in the dedication and focus our employees demonstrate, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD. If you share our passion for breaking new ground in the discovery and development of first-in-class therapeutics, and are dedicated to building a company centered on cutting-edge science that delivers new innovations to patients, then we would like to speak with you. We seek talented and high-achieving professionals to join us as we work towards bringing critically needed new therapies to patients.
South San Francisco, US
29 (est)+8%

Tricida Locations

South San Francisco, US

Tricida Metrics

Tricida Summary

Founding Date


Total Funding

$99.5 M

Latest funding size

$55 M

Time since last funding

3 months


Tricida Company Life